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Abstract
Purpose To analyse patient demographics, indications,
survival and donor characteristics for heart transplantation
(HTx) during the past 30 years at the University Medical
Centre Utrecht (UMCU).
Methods Data have been prospectively collected for all
patients who underwent HTx at the UMCU from 1985
until 2015. Patients who were included underwent ortho-
topic HTx at an age >14 years.
Results In total, 489 hearts have been transplanted since
1985; 120 patients (25%) had left ventricular assist device
(LVAD) implantation prior to HTx. A shift from ischaemic
heart disease to dilated cardiomyopathy has been seen as
the leading indication for HTx since the year 2000. Median
age at HTx was 49 years (range 16–68). Median waiting
time and donor age have also increased from 40 to 513
days and from 27 to 44 years respectively (range 11–65).
Donor cause of death is now primarily stroke, in contrast
to head and brain injury in earlier years. Estimated median
survival is 15.4 years (95% confidence interval 14.2–16.6)
There is better survival throughout these years.
Conclusion Over the past 30 years, patient and donor demo-
graphics and underlying diseases have shifted substantially.
Furthermore, the increase in waiting time due to lack of
available donor hearts has led to a rise in the use of LVADs
as bridge to transplant. Importantly, an improvement in sur-
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vival rates is found over time which could be explained
by better immunosuppressive therapy and improvements in
follow-up care.
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Introduction
Orthotopic heart transplantation (HTx) has been an effective
treatment for end-stage heart failure for many years and was
performed in more than 120,000 patients worldwide up until
2015 [1]. Since 1967, when the first HTx was performed by
Christiaan Barnard in South Africa, survival rates have in-
creased significantly [2]. In the early days, this was mainly
due to improvements in diagnosis and treatment of com-
plications such as acute rejection [3]. These improvements
were led by the introduction of the calcineurin inhibitors
cyclosporine in 1980, and tacrolimus several years later,
and the development of the bioptome, allowing diagnostic
endomyocardial biopsies for the histological diagnosis of
rejection. A systematic grading scale for the classification
of rejection was also very important [4].
Nowadays, the main limitation of HTx is the lack of
donor hearts worldwide. In the Netherlands the first HTx
was performed in Rotterdam in 1984 and in Utrecht in 1985,
after a long period of decision-making by the government.
To date, around 100 patients are on the national waiting
list, whereas approximately 45–50 patients are transplanted
each year. This lack of donor hearts leads to prolonged
waiting times. The limited availability of donor hearts is
partly compensated for by left ventricular assist devices
(LVADs), which are used to bridge patients with advanced
heart failure until a donor heart becomes available. Inter-
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estingly, the improved durability of LVADs makes them
suitable as a long-term alternative for HTx [3, 5, 6].
In this article we describe the demographics, indications,
survival and donor characteristics over the past 30 years in
patients who were transplanted at our centre.
Methods
Study design
This single-centre retrospective analysis included all pa-
tients ≥14 years of age who underwent orthotropic HTx at
our centre from 1985 until 2015. Data were collected from
a database containing prospectively registered heart trans-
plantations performed after 1985, and missing data were
collected from patient charts. For comparison over time,
patients were grouped into six clusters by year of trans-
plantation: (I) 1985–1989, (II) 1990–1994, (III) 1995–1999,
(IV) 2000–2004, (V) 2005–2009 and (VI) 2010–2014.
Screening, definition and in-house protocol
Patients were considered for HTx according to national
guidelines, last updated in 2008 [7]. Briefly, indication for
HTx is end-stage heart disease not amenable by more con-
servative measures. Since HTx is an intensive medical treat-
ment, the patient must be willing, capable and emotionally
stable to withstand the uncertainties likely to occur both
before and after transplantation. Furthermore, the expected
1-year mortality of the potential patient should exceed the
1-year mortality after HTx, which is 10–15%. An estima-
tion of the prognosis in patients with end-stage heart failure
is difficult but can be estimated using, for instance, the Heart
Failure Survival Score (HFSS) which consists of a combi-
nation of several non-invasive measures such as peak VO2,
ejection fraction and intraventricular conduction delay, and
the Seattle Heart Failure Model [8, 9].
Contraindications for HTx are defined as high pulmonary
vascular resistance (PVR), active systemic infection, active
malignancy, inability to comply with complex medical reg-
imen, severe peripheral or cerebrovascular disease and ir-
reversible dysfunction of another organ [6]. Nonetheless,
these contraindications are generally not absolute but only
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Table 1 Characteristics of heart transplantation recipients
Patient characteristics
Averages presented as means ± SD or median (IQ) when appropriate
HTx patients
n = 489
Range or percentage
Median age at transplantation (IQ) 49 (IQ 39–56) 16–68
<20 years (n, %)
20–40 years (n, %)
40–60 years (n, %)
>60 years (n, %)
10
126
306
47
2.0%
25.8%
62.6%
9.6%
Male n, % 372 76%
Pretransplant diagnosis (n, %)
Non-ischaemic dilated CMP
Ischaemic heart disease
Hypertrophic CMP
Restrictive CMP
Congenital heart disease
Valvular heart disease
Re-transplant
220
214
21
4
8
14
8
45%
43.8%
4.3%
0.8%
1.6%
(2.9%)
1.6%
Pretransplant BMI (±SD) 23.5 (±3.3) 13.7–34.9
Pretransplant PVR without intervention (±SD); (n = 471)
Pretransplant PVR with intervention (±SD); (n = 18)
Median pretransplant creatinine (IQ) (n = 483)
177 (±88)
230 (±92)
106 (IQ 89–127)
16-561
65–419
40–328
LVAD bridging, n (%)
Median time with LVAD on waiting list in days (IQ); (n = 117)
120
266 (IQ 147–484)
25%
(9–1384)
Median waiting time for transplantation in days, (IQ), (n = 486)
1985–1989
1990–1994
1995–1999
2000–2004
2005–2009
2010–2014
150 (IQ 48–301)
40 (IQ 16–84)
107 (IQ 41–162)
119 (IQ 43–249)
158 (IQ 56–259)
287 (IQ 119–463)
513 (IQ 257–806)
0–1688
0–262
3–653
0–559
1–1509
1–1235
1–1688
SD standard deviation, IQ interquartile range, CMP cardiomyopathy, BMI body mass index, PVR pulmonary vascular resistance, LVAD left
ventricular assist device
temporary and have to be judged in relation to the clinical
picture of the patient. As an example, irreversible elevated
PVR increases the risk of right-sided failure of the trans-
planted heart. However, there is no absolute cut-off value
so it has to be seen as an incremental risk factor.
After referral, the first step is optimisation of medical
therapy after which patients undergo screening for con-
traindications. Eligibility of patients is assessed by a ded-
icated team consisting of at least a cardiologist trained in
end-stage heart failure and transplantation, a cardiothoracic
surgeon, and specialised nurses. According to the guidelines
for HTx, patients are considered either: (1) not eligible for
HTx, (2) a future candidate for HTx or (3) listed for HTx
[7].
Patients on the waiting list, as well as the patients who
were deemed too good for transplantation at prior evalua-
tion, will be regularly re-evaluated given the dynamic nature
of the clinical course (Fig. 1).
Statistical analysis
Re-transplanted patients (n = 8) were listed as having
one primary indication, and a secondary indication named
‘other’. Survival data were gathered using the hospital pa-
tient information system. Group comparisons were made
using the chi-square test for categorical variables, the one-
way ANOVA and post-hoc test for normally distributed
continuous variables, and the Kruskal-Wallis or Mann-
Whitney U test for non-normally distributed continuous
variables when appropriate. Survival rates were calculated
using the Kaplan-Meier method and tests for trends were
performed using the log-rank test. Conditional survival
curves were analysed for patients surviving the first year
after HTx. Statistical significance was assumed at p < 0.05.
Statistical analyses were performed using IBM SPSS ver-
sion 21 for Windows (SPSS Inc., Chicago, Illinois, USA).
Graphs and sub-analysis were performed using GraphPad
Prism version 6.02 for Windows.
Results
This analysis includes 489 heart transplants in 481 patients
in the UMCU from 1985 until 2015 (Fig. 2; Table 1).
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Fig. 2 Number of transplants, indication for transplantation and median waiting time
Recipient characteristics
Over time a gradual increase in numbers of transplanta-
tions per year can be seen, with a peak in 1996 and de-
clining afterwards (Fig. 2a). Median age at HTx was 49
with an interquartile range (IQ) of 39–56 and has remained
constant throughout the years. Over 60% of our patients
were between 40–60 years of age at the time of trans-
plant. Our cohort was predominantly male (76%) with no
significant change over time. Primary indications for HTx
were non-ischaemic dilated cardiomyopathy (DCM) (220
patients, 45%) and ischaemic heart disease (214 patients,
44%), followed by hypertrophic cardiomyopathy (21 pa-
tients, 4.3%), acquired valvular disease (14 patients, 2.9%),
congenital heart disease (8 patients, 1.6%), restrictive car-
diomyopathy (4 patients, 0.8%) and re-transplants (8 pa-
tients, 1.6%) (Fig. 2c; Table 1). Comparing indication for
HTx, a significant shift can be seen (p = 0.028) in the num-
ber of recipients, from ischaemic heart disease to DCM over
the course of the groups (Fig. 2b; Table 1). Whereas only
40% of recipients were of DCM origin in the first 5 years,
this indication now comprises 57% of cases. Ischaemic
heart disease, however, decreased from 52 to 30% (Fig. 2b;
Table 2). Eight patients have had re-transplantations due to
primary graft failure of the first donor heart. BMI increased
from 22 to 24 over the years (p = 0.01). Mean PVR did not
show changes.
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Table 2 Significant change in demographics from 1985 to 2015
Change in demographics from 1985–1990 to 2010–2015
Averages presented as means ± SD or median (IQ) and p-value when appro-
priate
1985–1989 2010–2014 P-value
Pretransplant diagnosis
Non-ischaemic dilated CMP
Ischaemic heart disease
Hypertrophic CMP
Restrictive CMP
Congenital heart disease
Valvular heart disease
Other
40.5%
52.4%
2.4%
2.4%
2.4%
–%
–%
56.7%
29.9%
6.0%
1.5%
3.0%
–%
3.0%
0.028
Pretransplant BMI (±SD) 22 (±3.5) 24 (±3.7) 0.01
Median waiting time for transplantation in days (IQ) (n = 486) 40 (IQ 16–84) 513 (IQ 257–806) <0.001
Donor cause of death (n = 484)
Brain tumour (%)
Stroke (%)
Gunshot wound, (%)
Suicide (%)
Head and brain injury (%)
Unknown (%)
0%
30%
0%
2%
61%
7%
6%
65%
1%
10%
18%
3%
<0.001
SD standard deviation, IQ interquartile range, CMP cardiomyopathy, BMI body mass index
LVAD implantation in our centre began in 1993, first on
a small scale. In total 120 patients (25%) received LVAD
implantation prior to HTx and given the low numbers in the
early years, a significant increase (p < 0.0001) in use can
be observed later on with a median of 133 in 1990–1994
to a median of 594 days in 2010–2014. The average LVAD
support time was a mean of 364 ± 313 days, ranging from
9–1384 days.
Waiting time to transplantation
Overall median waiting time for transplantation was 150
(IQ 48–301) days with a range of 0–1688 days. A significant
(p < 0.001) increase in waiting time can be seen from a me-
dian of 40 days in 1985–1990 to 513 days in 2010–2014.
Since the introduction of continuous flow LVADs in 2006,
with proven longer durability, the waiting time has in-
creased even further (p = 0.001) (Fig. 2d; Table 1).
Survival
Kaplan-Meier data of total survival and conditional survival
(those patients who survived the first year after HTx) are
presented in Fig. 3. Median survival was 15.4 years (95%
confidence interval 14.2–16.6) for the entire cohort, includ-
ing 13 patients who have survived for over 25 years after
HTx. There is a significant trend towards better survival
when comparing the groups over time (Fig. 3).
Donor characteristics
Median donor age was 40 [IQ 28–48] years for the whole
cohort, but has increased significantly (p < 0.001) from
27 years to 44 years from 1985 to 2014. The oldest donor
was 65 years; 207 (43%) of our donors were female and 280
(57%) were male (Table 3). The cause of death was mainly
cerebral stroke (272, 57%) and head and brain injury (163,
34%). The remaining causes were brain tumours (14 = 3%),
suicide (11, 2%), gunshot wounds (3, 1%) and 15 (3%) of
unregistered cause. A significant (p < 0.001) shift in cause
of death, however, can be observed. In the early years of
HTx the major cause of death was head and brain injury
(over 60% of donors), this has come down to 18% in recent
years. The opposite holds true for stroke as a cause of death
for donors (29 to 65%) (Table 2).
Discussion
In this article we describe the demographics, indications
and survival of HTx and donor characteristics over the past
30 years.
Firstly, addressing to demographic trends, we see that
over the years DCM has replaced ischaemic heart disease
as the main reason for HTx in our cohort. Worldwide this
same trend can be observed [1, 7, 10–14]. One possible
explanation might be the better treatment of coronary artery
disease in itself, resulting in less patients with end-stage
heart failure at an age that still allows HTx. Overall, the
other characteristics of the recipients did not change very
much over time; as can be expected, it concerns more men
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Fig. 3 Overall survival, conditional survival and survival in groups
than women and the median age at which patients were
transplanted was around 50. These figures are comparable
with those from other European countries [12, 14].
Donor characteristics, however, did change dramatically
from predominantly traumatic events as cause of death in
the past to largely cerebrovascular events in more recent
years, accompanied by a significant increase in donor age
(median age 27 years in 1985, vs 44 years in 2014, with
extremes to 65 years.) This change encompasses an entirely
different risk profile of donors since hearts of older patients
with stroke, by definition, have more vascular comorbidi-
ties, affecting not only the eligibility of the donor heart, but
also result in an increased risk of coronary allograft vascu-
lopathy after transplantation [15, 16]. With respect to donor
age, Europe and especially the Netherlands completely di-
verge from the international data, as the median age of all
cardiac donors used worldwide (including European data) is
still only 35 years [1]. This has to be explained by the low
mortality of traffic accidents in the Netherlands in com-
parison with other countries [3]. But without using those
older donor hearts, almost no heart transplantations would
be performed in the Netherlands.
Despite the significantly higher donor age, we demon-
strate improved survival after HTx. This can be attributed
to several factors. Apart from the availability of better im-
munosuppressive therapy and growing experience with this
specific patient category in general, an important aspect is
that all our follow-up is performed in-house and not else-
where as in many other centres. Furthermore, international
statistics are negatively biased by many smaller centres per-
forming only a few transplantations per year and lacking
this experience. This improved experience is also related
to the treatment of complications such as cardiac allograft
vasculopathy, renal failure and malignancies [3, 10]. Fur-
thermore, because of the lack of donor hearts there is more
stringent selection of recipients in comparison with other
countries, potentially resulting in a younger transplantation
cohort than reported by the International Society for Heart
and Lung Transplantation (54 years) [1].
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Table 3 Characteristics of heart transplantation donors
Donor characteristics
Averages presented as means ± SD or median (IQ) when appropriate
N Range or percentage
Donor age in years (IQ) (n = 482) 40 (IQ 28–48) 11–65
Male, n (%) 280 57%
Donor cause of death (n = 477)
Brain tumour, n (%)
Stroke, n (%)
Gunshot wound, n (%)
Suicide, n (%)
Head and brain injury, n (%)
Unknown, n (%)
14
272
3
11
162
15
3%
57%
1%
2%
34%
3%
SD standard deviation, IQ interquartile range
Another remarkable change over time is the use of
LVADs as bridge to transplantation. This option was not
available at the start of the program in 1985, but nowadays
is an inseparable part of it. Due to the extremely long wait-
ing time until transplantation, many patients deteriorate
while on the waiting list. A large number of these patients
can now be treated by mechanical circulatory support, us-
ing an LVAD as bridge to transplantation, which potentially
causes deleterious displacement effects for the waiting time.
The dilemma now conceived is an even longer waiting time
as more patients survive until transplantation without an
accompanying increase in donor hearts. But without the use
of LVADs, many patients with acute heart failure would not
have made it to transplantation or even to the waiting list at
all. Clearly, implantation of an LVAD also implies periop-
erative risk but this outweighs the mortality of progressive
acute heart failure by far [17]. Furthermore, it has to be
realised that due to the improvements in technology and
design the durability of LVADs has increased substantially,
allowing the longer waiting time until transplantation, with
a remarkable good quality of life and exercise tolerance
[18, 19].
Conclusion
Over the past 30 years, substantial differences can be noted
in HTx. Patient demographics show a shift from ischaemic
heart disease to DCM. The donor situation has completely
changed from younger trauma victims to older patients dy-
ing from a cerebrovascular accident with a higher chance of
pre-existing cardiovascular abnormalities. Due to the longer
waiting time, an increasing number of patients have to be
bridged to transplantation by a LVAD.
Despite these potentially adverse aspects, there is an im-
provement in survival rates which could be explained by
better immunosuppressive therapy and improvements in fol-
low-up care.
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